ClinicalTrials.gg
RecruitingNCT06628687Updated Jul 10, 2026

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

An observational study in Friedreich Ataxia, sponsored by Biogen. Recruiting at 1 site in United States. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Biogen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
16 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Planned enrollment
19th of 21
10 · median 65
Started
2026
with 7 others
Observational
21 of 71
8 open now
Primary completion
2035-04
later than 22 of 24 live
Registered
58th of 71
by date
Lead sponsor
5 of 71
Biogen

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 19th largest by planned enrollment of the 21 observational ones that give a count, is one of 8 that started in 2026, is one of 21 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 58th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS. This is a drug available for doctors to prescribe for people with Friedrich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will have taken BIIB141 at any time during pregnancy and/or while breastfeeding or pumping up through the first year after delivery. Participants can join this study on their own or they may be enrolled by their regular doctors. This study is also known as the "SKYCLARYS (Omaveloxolone) Pregnancy and Lactation Surveillance Program."

The main objective of this study is to learn more about how BIIB141 may affect pregnancy, as well as any effects on the health of the mother and of the baby during its first year of life.

The main question researchers want to answer in this study is:

  • Does taking BIIB141 during pregnancy or breastfeeding lead to any major birth defects?

Researchers will also learn more about:

  • Does taking BIIB141 during pregnancy or breastfeeding lead to any minor birth defects?
  • Does taking BIIB141 during pregnancy or breastfeeding affect the following:
  • Gestational diabetes, a disease that can happen during pregnancy that affects how your body uses sugar
  • Pre-eclampsia, a pregnancy-related high blood pressure disease
  • Unborn baby being small for its expected age (usually in weeks)
  • Loss of an unborn baby
  • Live birth
  • Premature birth
  • Loss of a newborn
  • Growth or developmental delays in the baby
  • Serious illness in the baby resulting in hospitalization
  • Serious infections in the baby, or ones in babies with a weakened immune system

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.
  • During the study, health information from the participants' regular visits to their doctor will be collected based on whether participant joined the study while pregnant or after the baby is born.
  • Each participant will be in the study for up to 1 year after the birth of their child, unless they decide to leave early. Overall, this study is expected to last at least 10 years.
Read the detailed description

The objective is to conduct a worldwide descriptive study to collect prospective and retrospective data in women exposed to omaveloxolone during pregnancy and/or lactation to assess risk associated with pregnancy, the maternal complications, and adverse effects on the developing fetus, neonate, and infant (through at least the first year of life) in the post-marketing setting.

03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include participants with FA who were exposed to omaveloxolone at any time during pregnancy and/or lactation.

Participants will be enrolled prospectively and retrospectively. Women who enroll prior to pregnancy outcome, and/or prior to start of breastfeeding will be enrolled as prospective participants. Women who enroll after the pregnancy has occurred and/or following the start of breastfeeding will be enrolled as retrospective participants. Retrospective participants will not be included in the analysis population. For prospective and retrospective participants exposed during lactation only, data will be reported separately from pregnancy exposure cases.

Eligibility criteria

Key Inclusion Criteria:

- Exposure to omaveloxolone for FA at any time during pregnancy (from 12 days prior to conception to pregnancy outcome) and/or at any time during lactation (up to 1 year of infant age or weaning, whichever comes first).

Key Exclusion Criteria:

- Not having exposure to omaveloxolone for FA.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Omaveloxolone

    Participants with FA who were exposed to omaveloxolone at any time during pregnancy (from 12 days prior to conception through the end of pregnancy outcome), and/or at any time during lactation (up to 1 year of infant age or weaning, whichever comes first).

    Drug: Omaveloxolone

Interventions

  • Administered as specified in the treatment arm.

    Also known as: SKYCLARYS, BIIB141, RTA 408

06

What researchers measure

Primary outcomes

  1. Number of Major Congenital Malformations (MCMs)

    A MCM is defined as an abnormality of body structure or function that is present at birth; is of prenatal origin (i.e., birth defect); has significant medical, social, or cosmetic consequences for the affected participant; and typically requires medical intervention.

    Time frame: Up to 10 years

Secondary outcomes

  1. Number of Minor Congenital Malformations

    Minor congenital malformations include an anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected participant.

    Time frame: Up to 10 years

  2. Number of Participants With Gestational Diabetes

    Time frame: Up to 9 months

  3. Number of Participants With Pre-eclampsia

    Time frame: Up to 9 months

  4. Number of Fetal Loss

    A fetal loss that occurs for any reason at any time during pregnancy will be reported.

    Time frame: Up to 9 months

  5. Number of Spontaneous Abortions

    Spontaneous abortion refers to an involuntary fetal loss or the expulsion of the products of conception occurring prior to 20 gestational weeks.

    Time frame: Up to 9 months

  6. Number of Stillbirths

    Still birth refers to an involuntary fetal loss occurring at or after 20 gestational weeks or, if gestational age is unknown, a fetus weighing ≥ 350 grams (g).

    Time frame: Up to 9 months

  7. Number of Elective or Therapeutic Abortion

    Elective or therapeutic abortion refers to a voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or due to fetal abnormalities.

    Time frame: Up to 9 months

  8. Number of Live Births

    Live birth refers to the birth of a living fetus after 20 weeks of gestation or, if gestational age is unknown, weighing ≥ 350 g.

    Time frame: Up to 9 months

  9. Number of Preterm Births

    Preterm birth refers to a live birth at or before 37 weeks of gestation.

    Time frame: Up to 9 months

  10. Number of Small for Gestational Age (SGA)

    SGA is defined as birth weight less than 10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants.

    Time frame: Up to 9 months

  11. Number of Neonatal Deaths

    Neonatal death refers to the death of a live-born infant within the first 28 days of life.

    Time frame: Within 28 days postdelivery

  12. Number of Infant Deaths

    Infant death refers to the death of a live-born infant within the first year of life.

    Time frame: Up to approximately 1 year

  13. Number of Infants with Abnormal Postnatal Growth and Development

    Infant growth measurements will be used to estimate gender-specific weight-for-length, head circumference-for-age, length-for-age, and weight-for-age percentiles. Developmental milestones (i.e., social/emotional, language/communication, neurocognitive, movement/physical development) will be evaluated to determine results of infant status (i.e., infants who are failing to achieve at least one milestone in any category will be considered developmentally delayed in that category).

    Time frame: Up to approximately 1 year

  14. Number of Infant Hospitalization due to Serious Illness

    Infant hospital visit due to a serious (that is, results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important) illness will be reported.

    Time frame: Up to 1 year

  15. Number of Infant Serious or Opportunistic Infections

    Infections that occur within an infant's first year of life and is either opportunistic (i.e., occurs more often or is more severe in people with weakened immune systems than in people with healthy immune systems) or serious (that is, results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important) will be reported.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Evidera
    Morrisville, North Carolina 27560, United States
    Recruiting
    • · Contact919-270-6678
    • Ronna Chan · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2035, 102 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 8, 2024
StartEst.
Oct 26, 2026
Primary completionEst.
Apr 30, 2035
CompletionEst.
Apr 30, 2035
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06628687
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Oct 26, 2026 (estimated)
Primary completion
Apr 30, 2035 (estimated)
Completion
Apr 30, 2035 (estimated)
Last update
Jul 10, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion